不同化疗方案治疗晚期及进展期霍奇金淋巴瘤的临床分析

Clinical analysis of different chemotherapy regimens in the treatment of advanced stage Hodgkin＇s lymphoma

目的探讨晚期及进展期霍奇金淋巴瘤患者采用不同化疗方案进行治疗的不良反应及临床疗效。方法选取2012年10月至2013年10月收治的46例晚期及进展期霍奇金淋巴瘤患者，依照随机分组方式分为观察组与对照组，每组23例，观察组采用BEACOPP化疗方案进行治疗，对照组采用ABVD化疗方案进行治疗，观察并比较两组患者的近期疗效、远期疗效与不良反应。结果观察组5年OS率为95．7％，对照组为73．9％，观察组5年总生存率明显高于对照组（P〈0．05），但两组不良反应发生率及5年无病生存率比较差异均未见统计学意义（P〉0．05）。结论晚期及进展期霍奇金淋巴瘤患者采用BEACOPP化疗方案治疗的远期疗效较好，不同化疗方案临床治疗均为有效且不良反应相仿。

Objective To investigate the adverse reactions and clinical effect of different chemo- therapy regimens on advanced Hodgkin lymphoma patients. Methods Forty-six patients were selected as the research objects from October 2012 to October 2013. All of them were divided into observation group and control group, and each group had 23 cases. The patients in observation group were given BEACOPP chemotherapy for treatment. The patients of control group were given ABVD chemotherapy for treatment. The short-term, long-term efficacy and adverse reactions of the two groups were observed and compared. Results The 5 year OS rate was 95.7 % in the observation group, and was 73.9% in the control group. The 5 year overall survival rate of observation group was significantly higher than that of the control group （P 〈0. 05）. But the observation group and the control group had no significant difference in the incidence of adverse reactions 5 year disease free survival rate （ P 〉 0. 05 ）. Conclusions The long-term effect of BEACOPP regimen on advanced Hodgkin lymphoma is good, different chemotherapy regimens are effective and adverse reactions are similar.